CRBP vs. LTRN, LPTX, ORGS, CEMI, TNXP, ZLAB, KROS, NAMS, HRMY, and EVO
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Lantern Pharma (LTRN), Leap Therapeutics (LPTX), Orgenesis (ORGS), Chembio Diagnostics (CEMI), Tonix Pharmaceuticals (TNXP), Zai Lab (ZLAB), Keros Therapeutics (KROS), NewAmsterdam Pharma (NAMS), Harmony Biosciences (HRMY), and Evotec (EVO). These companies are all part of the "pharmaceutical preparations" industry.
Corbus Pharmaceuticals (NASDAQ:CRBP) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability.
Corbus Pharmaceuticals received 419 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 66.41% of users gave Corbus Pharmaceuticals an outperform vote.
Corbus Pharmaceuticals presently has a consensus price target of $61.00, suggesting a potential upside of 42.52%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Corbus Pharmaceuticals is more favorable than Lantern Pharma.
Lantern Pharma has lower revenue, but higher earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.
Corbus Pharmaceuticals has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.
In the previous week, Lantern Pharma had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for Lantern Pharma and 4 mentions for Corbus Pharmaceuticals. Lantern Pharma's average media sentiment score of 0.89 beat Corbus Pharmaceuticals' score of 0.53 indicating that Lantern Pharma is being referred to more favorably in the news media.
Lantern Pharma's return on equity of -41.17% beat Corbus Pharmaceuticals' return on equity.
64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 4.0% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 6.9% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Lantern Pharma beats Corbus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
